Collegium Pharmaceutical (COLL) Competitors $30.15 -0.41 (-1.34%) As of 03/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. SWTX, RARE, AKRO, ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, and MRUSShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. SpringWorks Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Alvotech Immunovant Viking Therapeutics Rhythm Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Merus SpringWorks Therapeutics (NASDAQ:SWTX) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking. Is SWTX or COLL more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to SpringWorks Therapeutics' net margin of -134.73%. Collegium Pharmaceutical's return on equity of 104.67% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SpringWorks Therapeutics-134.73% -46.74% -41.12% Collegium Pharmaceutical 14.78%104.67%18.38% Does the media favor SWTX or COLL? In the previous week, Collegium Pharmaceutical had 7 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 14 mentions for Collegium Pharmaceutical and 7 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.93 beat Collegium Pharmaceutical's score of 0.90 indicating that SpringWorks Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SpringWorks Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, SWTX or COLL? Collegium Pharmaceutical has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpringWorks Therapeutics$191.59M18.47-$325.10M-$3.48-13.57Collegium Pharmaceutical$631.45M1.50$48.15M$1.8616.21 Does the MarketBeat Community prefer SWTX or COLL? Collegium Pharmaceutical received 282 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 71.62% of users gave SpringWorks Therapeutics an outperform vote while only 65.32% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformSpringWorks TherapeuticsOutperform Votes10671.62% Underperform Votes4228.38% Collegium PharmaceuticalOutperform Votes38865.32% Underperform Votes20634.68% Do analysts prefer SWTX or COLL? SpringWorks Therapeutics presently has a consensus price target of $73.20, suggesting a potential upside of 55.05%. Collegium Pharmaceutical has a consensus price target of $43.60, suggesting a potential upside of 44.61%. Given SpringWorks Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe SpringWorks Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SpringWorks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, SWTX or COLL? SpringWorks Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. SummaryCollegium Pharmaceutical beats SpringWorks Therapeutics on 10 of the 16 factors compared between the two stocks. Remove Ads Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$949.30M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio13.007.2324.5519.25Price / Sales1.50230.77395.7294.10Price / Cash2.7665.6738.1634.64Price / Book5.036.617.064.46Net Income$48.15M$142.13M$3.19B$247.07M7 Day Performance1.01%1.72%0.18%1.77%1 Month Performance6.35%2.31%5.54%-3.31%1 Year Performance-24.49%-5.07%14.22%5.26% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical4.0374 of 5 stars$30.15-1.3%$43.60+44.6%-24.9%$949.30M$631.45M13.00210Analyst ForecastSWTXSpringWorks Therapeutics2.8992 of 5 stars$49.84-2.5%$73.20+46.9%-4.5%$3.73B$191.59M-14.32230RAREUltragenyx Pharmaceutical4.3754 of 5 stars$39.64+0.8%$91.71+131.4%-14.8%$3.67B$560.23M-6.251,276Positive NewsAKROAkero Therapeutics4.2234 of 5 stars$44.82+1.5%$76.29+70.2%+87.2%$3.57BN/A-11.9530ALVOAlvotech2.0135 of 5 stars$11.31+0.1%$18.00+59.2%-12.1%$3.41B$391.87M-6.111,026Upcoming EarningsIMVTImmunovant2.5091 of 5 stars$20.02+2.6%$42.90+114.3%-41.7%$3.40BN/A-7.64120VKTXViking Therapeutics4.4815 of 5 stars$29.83-3.4%$97.67+227.4%-59.6%$3.35BN/A-29.8320Positive NewsRYTMRhythm Pharmaceuticals4.2976 of 5 stars$52.34+2.7%$69.31+32.4%+33.4%$3.31B$130.13M-12.09140Analyst ForecastAnalyst RevisionSRRKScholar Rock3.688 of 5 stars$34.72+0.3%$40.43+16.4%+107.9%$3.29B$33.19M-14.77140Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals4.3199 of 5 stars$35.20+2.1%$72.64+106.4%-18.7%$3.28B$1.04M-9.44210Analyst ForecastPositive NewsMRUSMerus2.0176 of 5 stars$47.22+0.3%$85.31+80.7%+5.0%$3.26B$36.13M-11.9537 Remove Ads Related Companies and Tools Related Companies SWTX Competitors RARE Competitors AKRO Competitors ALVO Competitors IMVT Competitors VKTX Competitors RYTM Competitors SRRK Competitors CRNX Competitors MRUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
